August 2012
-
DFE Pharma has announced the launch of a new product in its range of Lactohale inhalation grade lactose products; Lactohale 400 milled anhydrous lactose is described as a grade for formulations “where a relatively good… Read more . . .
-
Orexo announced the initiation of a Phase 1 trial of its OX640 intranasal dry powder adrenaline, which the company is developing for emergency treatment of anaphylaxis. The OX640-001 study will compare several formulations of OX640… Read more . . .
-
Receptor Life Sciences said that a Phase 1b/2a trial of its RLS103 cannabidiol DPI in social anxiety disorder patients with acute anxiety has gotten underway. The trial is expected to enroll approximately 30 patients who… Read more . . .
-
Altamira Therapeutics (formerly Auris Medical) announced that the company has received 510(k) clearance to sell its Bentrio Allergy Blocker nasal spray over the counter for the treatment of allergic rhinitis in the US. The company… Read more . . .
-
FluGen said that the first subject has been dosed in a Phase 1b study of its M2SR intranasal live single replication flu vaccine and an intramuscular high dose inactivated vaccine (IIV) in adults aged 65 to… Read more . . .
-
Device maker H&T Presspart has announced the opening of a new laboratory scale facility at its Blackburn, UK Inhalation Product Technology Centre (IPTC) for filling metered dose inhalers with lower global warming potential (GWP) propellants, including… Read more . . .
-
Padagis, formerly Perrigo’s generic prescription pharmaceutical business, has announced the launch of a generic version of Narcan naloxone nasal spray for the reversal of opioid overdose. The Padagis generic is the second approved in the… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of an inhaled dry powder fixed dose combination of indacaterol and mometasone furoate for the treatment of asthma which is being marketed under the name “Indamet”. All three of… Read more . . .
-
Savara announced that the UK Medicines and Healthcare Products Regulatory Agency has awarded an Innovation Passport to molgramostim inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The Innovation… Read more . . .
-
Acorda Therapeutics announced that Inbrija levodopa inhalation powder has been launched in Germany by Esteve Pharmaceuticals. The EMA approved Inbrija DPI for the treatment of OFF periods in Parkinson’s disease in 2019. Acorda said that… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.